

## Curriculum vitae Soraya Puglisi

### Personal details

Born in Taormina (ME)

Nationality: Italian

Email: [soraya.puglisi@unito.it](mailto:soraya.puglisi@unito.it)

ORCID ID: 0000-0002-2883-6139; Scopus ID: 55936036500; Researcher ID: AAB-9961-2019

### Educations

October 19<sup>th</sup>, 2021 - **PhD in Medicine and Experimental Therapy**

Institution: University of Turin

Thesis title: *“A new method to determine the optimal exposure to mitotane treatment in patients with adrenocortical carcinoma”*

Supervisors: Prof. Massimo Terzolo

Grade: cum laude

July 14<sup>th</sup>, 2017 - **Postgraduate Degree: Endocrinology and Metabolic Diseases Specialist**

Institution: University of Catania

Thesis title: *“Effetti del mitotane sull'asse ipotalamo-ipofisi-surrene in pazienti con carcinoma del corticosurrene”*

Supervisors: Prof. Cannavò Salvatore, Prof. Massimo Terzolo

Grade: 70/70 cum laude

July 20<sup>th</sup>, 2011 – **Degree in Medicine and Surgery**

Institution: University of Messina

Thesis title: *“Caratteristiche cliniche e biochimiche dei pazienti con acromegalia resistente alla terapia con analoghi della somatostatina”*

Supervisors: Prof. Cannavò Salvatore

Grade: 110/110 cum laude

### Professional experiences and current position

From July 1<sup>st</sup>, 2021 (ongoing) – **Researcher type A (Junior Assistant professor) - University of Turin**

Department of Clinical and Biological Sciences - San Luigi Gonzaga Hospital

10043 Orbassano-Torino, Italy

### Honors

Winner of the **BEST POSTER AWARD** at the V National Congress of the SIE (Italian Society of Endocrinology) Club "ONCOLOGICAL ENDOCRINOLOGY" (June 30/ July 2, 2022 Siracusa): "Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial"

Winner of the **FIRST PRIZE “Premia la tua Tesi” (Thesis Award)**

20° National Congress AME (Associazione Medici Endocrinologi), 11-14 Novembre 2021 – Trieste

Winner of the **BEST ORAL PRESENTATION AWARD - ENS@T FLASH TALK 2021 – ACC clinical** at the congress “JOINT 20<sup>th</sup> ENSAT MEETING AND 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM 2021”(eMeeting – Brescia 30/09-02/10/2021): "Outcome of patients with adrenocortical cancer in Italy: a population-based study"

Winner of the Prize in memory of dr. Nunzio Romeo – 1st edition for Endocrinologist of University of Messina (December 2018)

Winner of the **BEST ORAL PRESENTATION AWARD** at the 4° National Congress CLUB SIE (Italian Society of Endocrinology) “ONCOLOGICAL ENDOCRINOLOGY” (November 15-16, 2018 – Ferrara): “Prognostic Factors in patients with non-metastatic adrenocortical carcinoma: the San Luigi Hospital Experience”

Winner of the **BEST ORAL PRESENTATION AWARD** at the congress “Parliamo di Ma.R.E” (Rare Endocrine Disease) (October 20-21, 2017 – Messina): “Preoperative Treatment With Metyrapone In Patients With Cushing's Syndrome Due To Adrenal Adenoma: A Pilot Prospective Study”

Winner of the **BEST POSTER AWARD** at the 3° National Congress CLUB SIE (Italian Society of Endocrinology) “ONCOLOGICAL ENDOCRINOLOGY (November 17-19, 2016 – Turin): “Mitotane effects on the hypothalamic pituitary adrenal axis in patients with adrenocortical carcinoma”

**Associate Editor** for *Frontiers in Endocrinology* (IF 6.055, Q1) - Section Adrenal

**Guest editor:**

- *Frontiers in Endocrinology* (IF 6.055, Q1)  
*Special Issue "Subclinical Hormonal Activity in Adrenal Tumors"*
- *Journal of Personalized Medicine* (IF 4.433, Q1)  
*Special issue: "Personalized Medicine in Adrenocortical Cancer"*

**Teaching activity:**

- 2022-2023 – Teacher of the Course “Internal Medicine 2” (SCB0227) of the Master’s Degree in “Medicine and Surgery”, University of Turin
- 2019-2022 – Teaching assistant of the ADE “Adrenal diseases that matter for internal medicine” (SCB0382) of the Master’s Degree in “Medicine and Surgery”, University of Turin
- 2018-2022 – Teaching assistant of the Course “Medicina Interna” (MSL0266D) of the Bachelor’s Degree in “Infermieristica” (Orbassano), University of Turin
- 2018-2022 – Teaching assistant of the Course “Medicina Interna” (MSL0266D) of the Bachelor’s Degree in “Infermieristica” (Cuneo), University of Turin

**Research main topics**

- Pathophysiologic and clinical features of adrenal tumors (characterization of incidentally discovered adrenal masses, definition of diagnostic aspects of autonomous cortisol secretion and other hormonal secretion, assessment of their clinical impact)
- Diagnostic, prognostic and therapeutic approaches for patients with adrenocortical carcinoma (evaluation of new diagnostic techniques, assessment of prognostic factors and development of advanced therapeutic modalities for adrenocortical carcinoma);
- Pathophysiologic and clinical features of Cushing's syndrome (study of the atypical variants of Cushing's syndrome and the efficacy of specific diagnostic tests, and assessment of the systemic effects of hypercortisolism);
- Systemic effects of GH and IGF-I in acromegaly (assessment of the clinical consequences of GH and IGF-I excess with particular focus on the relationship between the GH-IGF axis and the neoplastic and cardiovascular risk in acromegalic patients).

**Bibliometry** ([www.scopus.com](http://www.scopus.com))

Dr. Puglisi has published 48 full papers on peer reviewed international journals (20 as first or co-first, 13 as corresponding author).

The impact factor of her papers is 255.423, the number of citations is 535 with H-index 15 (Scopus).

## **Publications**

New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study.

**Puglisi S**, Calabrese A, Ferrà F, .... Cannavò S, Terzolo M.

*J Clin Endocrinol Metab* 2023; dgad199. doi: 10.1210/clinem/dgad199. IF 6.134 Q1

**\*First author \*\*Corresponding author**

Italian Guidelines For The Management Of Non-Functioning Benign And Locally Symptomatic Thyroid Nodules.

Papini E, Crescenzi A, D'Amore A, ....**Puglisi S**, ....., Attanasio R.

*Endocr Metab Immune Disord Drug Targets* 2023. doi: 10.2174/1871530323666230201104112 IF 2.387 Q4

The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients.

Calabrese A, **Puglisi S\*\***, Borin C, Basile V, Perotti P, Pia A, Berchiolla P, Volante M, Fiori C, Porpiglia F, Veltri A, Reimondo G, Terzolo M.

*Eur J Endocrinol.* 2023; 188(1):lvad002. doi: 10.1093/ejendo/lvad002. IF 6.558 Q1

**\*\*Corresponding author**

Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.

**Puglisi S\***, Basale V, Sperone P, Terzolo M.

*Reviews in Endocrine and Metabolic Disorders* 2022; doi:10.1007/s11154-022-09769-y IF 9.306 Q1

**\*First author**

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.

Allegra S, **Puglisi S**, Borin C, Chiara F, Basile V, Calabrese A, Reimondo G, De Francia S.

*Biomedicines* 2022; 10:1873. doi: 10.3390/biomedicines10081873 IF 4.757 Q2

Prevalence of Metabolic Syndrome and Insulin Resistance in a Sample of Adult ADHD Outpatients.

di Girolamo G, Bracco IF, Portigliatti Pomeri A, **Puglisi S**, Oliva F.

*Front. Psychiatry* 2022; 13:891479. doi: 10.3389/fpsy.2022.891479 IF 5.435 Q2

Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study.

Deutschbein T, Reimondo G, Di Dalmazi G, Bancos I, Patrova J, Vassiliadi DA, .... **Puglisi S**, ...Terzolo M, Fassnacht M.

*Lancet Diabetes Endocrinol* 2022; doi: 10.1016/S2213-8587(22)00110-3. IF 44.867 Q1

Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas.

**Puglisi S\*\***, Leporati M, Amante E, Parisi A, Pia A.R, Berchiolla P, Terzolo M, Vincenti M, Reimondo G.

*Front Endocrinol* 2022; 13:833514. doi: 10.3389/fendo.2022.833514. IF 6.055 Q1

**\*First author \*\*Corresponding author**

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, **Puglisi S**, Bali U, Moraitis AG.

*Front Endocrinol* 2022; 12:793262 doi: 10.3389/fendo.2021.793262 IF 6.055 Q1

A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma / Paraganglioma Patients in Italy

Canu L\*, **Puglisi S\***, Berchiolla P,..... Reimondo G.

*Cancers* 2021, 13: 5831 doi: 10.3390/cancers13225831 IF 6.575 Q1

**\*Joint First author**

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System

**Puglisi S\***, Rossini A\*, Poli R, Dughera F, Pia A, Terzolo M, Reimondo G.

*Front Endocrinol* 2021; 12:738848. doi: 10.3389/fendo.2021.738848 IF 6.055 Q1

**\*Joint First author**

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies.

Lo Iacono M, **Puglisi S\*\***, Perotti P, Saba L, Pia A, Petiti J, Giachino C, Reimondo G, Terzolo M.

*Cancers* 2021; 13: 5255. doi: 10.3390/cancers13215255 IF 6.575 Q1

**\*\*Corresponding author**

Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report.

Osella G, **Puglisi S\*\***, Ali A, Reimondo G, Terzolo M.

*Endocr Metab Immune Disord Drug Targets*. 2021 Jul 8. doi: 10.2174/1871530321666210708142127. IF 2.387 Q4

**\*\*Corresponding author**

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.

Basile V\*, **Puglisi S\*\***, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchiolla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M.

*J Pers Med* 2021, 11:269; doi:10.3390/jpm11040269. IF 3.508 Q2

**\*Joint First author \*\*Corresponding author**

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma.

Allegra S, **Puglisi S**, Brescia I, Chiara F, Basile V, Calabrese A, Reimondo G, De Francia S.

*Life* 2021, 11:266; doi: 10.3390/life11030266. IF 3.253 Q2

Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in childhood and adolescence.

Giovinazzo S\*, **Puglisi S\***, Cotta OR, Alibrandi A, Aversa T, Cannavò L, Ferrau F, Cannavò S.

*Pituitary* 2021; doi: 10.1007/s11102-020-01123-2. IF 3.599 Q3

**\*Joint First author**

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.

Geer EB, Salvatori R, Elenkova A, Fleseriu M, Pivonello R, Witek P, Feelders RA, Bex M, Borresen SW, **Puglisi S**, Biller BMK, Cohen F, Pecori Giraldi F.

*Pituitary* 2021; 24: 104-115. doi:10.1007/s11102-020-01103-6. IF 3.599 Q3

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer.

Basile V\*, **Puglisi S\***, Calabrese A, Pia A, Perotti P, Berruti A, Reimondo G, Terzolo M.

*Cancers* 2020; 12:E2615. doi:10.3390/cancers12092615. IF 6.639 Q1

**\*Joint First author**

What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study.

**Puglisi S\*\***, Rossini A\*, Tabaro I, Cannavò S, Ferrau F, Ragonese M, Borretta G, Pellegrino M, Dughera F, Parisi A, Latina A, Pia A, Terzolo M, Reimondo G.

*J Endocrinol Invest* 2020; doi: 10.1007/s40618-020-01386-3. IF 4.256 Q2

**\*Joint First author \*\*Corresponding author**

Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population?

Terzolo M, **Puglisi S\*\***, Reimondo G, Dimopoulou C, Stalla G.

*Eur J Endocrinol* 2020; 183: D1-D13. pii: EJE-19-1009. doi: 10.1530/EJE-19-1009 IF 6.664 Q1

**\*\*Corresponding author**

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.

Germano A, Rossin D, Leoni V, Iaia N, Saba L, Basile V, **Puglisi S**, Caccia C, Poli G, Biasi F, Terzolo M.

*Cells* 2020; 9:885. doi: 10.3390/cells9040885. IF 6.600 Q2

Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation.

Veltri A, Basile D, Calandri M, Bertaggia C, Volante M, Porpiglia F, Calabrese A, **Puglisi S**, Basile V, Terzolo M.

*Eur Radiol* 2020; 30: 6958-6964. doi: 10.1007/s00330-020-07019-w. IF 5.315 Q1

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma

**Puglisi S\***, Calabrese A, Basile V, .... Terzolo M.

*Cancers* 2020; 12:740; doi:10.3390/cancers12030740 IF 6.639 Q1

**\*First author**

Is Follow-up of Adrenal Incidentalomas Always Mandatory?

Reimondo G, Muller A, Ingargiola E, **Puglisi S\*\***, Terzolo M.

*Endocrinol Metab* 2020; 35:26-35. doi:10.3803/EnM.2020.35.1.26 IF 4.010 Q3

**\*\*Corresponding author**

New perspectives for mitotane treatment of adrenocortical carcinoma.

**Puglisi S**, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, Terzolo M.

*Best Pract Res Clin Endocrinol Metab* 2020; 34:101415. doi:10.1016/j.beem.2020.101415 **IF 4.690 Q2**

**\*First author**

May an adrenal incidentaloma change its nature?

Muller A, Ingargiola E, Solitro F, Bollito E, Puglisi S\*\*, Terzolo M, Pia A, Reimondo G.

*J Endocrinol Invest* 2020; 43:1301-1307. doi:10.1007/s40618-020-01219-3 **IF 4.256 Q2**

**\*\*Corresponding author**

Recovery of Adrenal Insufficiency is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma

Poirier J, Gagnon N, Terzolo M, **Puglisi S**, El Ghorayeb N, Calabrese A, Lacroix A, Bourdeau I. *Cancers* 2020; 12:639 doi: 10.3390/cancers12030639 **IF 6.639 Q1**

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.

**Puglisi S\***, Ferrau F, Ragonese M, Spagnolo F, Cannavò S.

*Front Endocrinol* 2020; 11:28. doi: 10.3389/fendo.2020.00028. **IF 5.555 Q1**

**\*First author**

Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study.

Reimondo G, Castellano E, Grosso M, **Puglisi S\*\***, Pia A, Pellegrino M, Borretta G, Terzolo M.

*J Clin Endocrinol Metab* 2020; 105:dgz284. doi:10.1210/clinem/dgz284 **IF 5.958 Q1**

**\*\*Corresponding author**

Prolonged Adrenal Insufficiency After Discontinuation of Mitotane Therapy.

Muratori L, Pia A, Reimondo G, Pisano C, La Salvia A, **Puglisi S**, Scagliotti GV, Sperone P.

*Endocr Metab Immune Disord Drug Targets* 2020; 20:485-487.

doi: 10.2174/1871530319666190809144620 **IF 2.895 Q3**

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment.

**Puglisi S\***, Calabrese A, Basile V, Ceccato F, Scaroni C, Simeoli C, Torlontano M, Cannavò S, Arnaldi G, Stigliano A, Malandrino P, Saba L, Altieri B, Della Casa S, Perotti P, Berchiolla P, De Filpo G, Canu L, Loli P, Reimondo G, Terzolo M.

*J Clin Med* 2019; 8:1850. doi: 10.3390/jcm8111850 **IF 3.303 Q1**

**\*First author**

Hypertension and acromegaly.

**Puglisi S\***, Terzolo M.

*Endocrinol Metab Clin North Am* 2019; 48:779-793. doi: 10.1016/j.ecl.2019.08.008 **IF 3.813 Q2**

**\*First author**

Mitotane: new facts for an old drug.

Calabrese A\*, **Puglisi S\***, Basile V, Perotti P, Terzolo M.

*Curr Opin Endocr Metab Res* 2019; 8:145-151. doi: 10.1016/j.coemr.2019.08.010

**\*Joint First author**

Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.

Calabrese A, Basile V, **Puglisi S\*\***, ... Terzolo M.

*Eur J Endocrinol.* 2019; 180:387-396. pii: EJE-18-0923.R2. doi: 10.1530/EJE-18-0923. **IF 5.308 Q1**

**\*\*Corresponding author**

Determination of salivary cortisol to assess time-related changes of the adrenal response to stress in critically ill patients.

**Puglisi S\***, Pizzuto A\*, Laface B, Panero F, Aprà F, Palmas E, Perotti P, Reimondo G, Boccuzzi A, Terzolo M.

*Eur J Intern Med* 2019; 68:66-70. doi: 10.1016/j.ijim.2019.08.001 **IF 4.329 Q1**

**\*Joint First author**

First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy.

**Puglisi S\***, Spagnolo F, Ragonese M, Cannavò S, Ferrau F.

*Growth Horm IGF Res* 2019; 45:17-19. doi: 10.1016/j.ghir.2019.02.001. **IF 1.618 Q4**

**\*First author**

Autonomous hypercortisolism: definition and clinical implications.

Reimondo G, **Puglisi S**, Pia A, Terzolo M.

*Minerva Endocrinol* 2019; 44:33-42. doi: 10.23736/S0391-1977.18.02884-5. **IF 1.817 Q4**

GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly.

Ferrau F, Romeo PD, **Puglisi S**, Ragonese M, Spagnolo F, Salpietro C, Ientile R, Currò M, Visalli G, Alibrandi A, Picerno IAM, Cannavò S. *J Endocrinol Invest* 2019; 42:825-831. doi: 10.1007/s40618-018-0988-8. **IF 3.439 Q2**

Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma.

**Puglisi S\***, Perotti P, Barbot M, Cosio P, Scaroni C, Stigliano A, Lardo P, Morelli V, Polledri E, Chiodini I, Reimondo G, Pia A, Terzolo M. *Endocr Connect* 2018; 7:1227-35. doi: 10.1530/EC-18-0400 **IF 2.474 Q3**

**\*First author**

Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.

**Puglisi S\***, Perotti P, Cosentini D, Roca E, Basile V, Berruti A, Terzolo M.

*Expert Rev Anticancer Ther* 2018; 18:1125-1133. doi: 10.1080/14737140.2018.1510325 **IF 2.571 Q3**

**\*First author**

Adrenocortical Carcinoma with Hypercortisolism.

**Puglisi S**, Perotti P, Pia A, Reimondo G, Terzolo M.

*Endocrinol Metab Clin North Am* 2018; 47:395-407. doi: 10.1016/j.ecl.2018.02.003 **IF 3.306 Q2**

**\*First author**

How to improve effectiveness of pegvisomant treatment in acromegalic patients.

Ragonese M, Grottoli S, Maffei P, Alibrandi A, Ambrosio MR, Arnaldi G, Bianchi A, **Puglisi S**, Zatelli MC, De Marinis L, Ghigo E, Giustina A, Maffezzoni F, Martini C, Tremantino L, Cannavò S.

*J Endocrinol Invest* 2018; 41:575-581. doi: 10.1007/s40618-017-0773-0. **IF 3.166 Q2**

Mitotane effects on the hypothalamic pituitary adrenal axis in patients with adrenocortical carcinoma.

Reimondo G, **Puglisi S\*\***, Zaggia B, Basile V, Saba L, Perotti P, De Francia S, Volante M, Zatelli MC, Cannavò S, Terzolo M.

*Eur J Endocrinol* 2017; 177:361-367. doi: 10.1530/EJE-17-0452. **IF 4.333 Q1**

**\*\*Corresponding author**

Analysis of BCL11, N363S and ER22/23EK polymorphisms of the glucocorticoid receptor gene in adrenal incidentaloma.

Reimondo G, Chiodini I, **Puglisi S**, Pia A, Morelli V, Kastelan D, Cannavò S, Berchiolla P, Giachino D, Perotti P, Cuccurullo A, Paccotti P, Beck-Peccoz P, De Marchi M, Terzolo M.

*PLoS One* 2016; 11: e0162437. doi: 10.1371/journal.pone.0162437. **IF: 2.806 Q1**

Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted area.

Cannavò S, Ragonese M, **Puglisi S**, Romeo PD, Torre ML, Alibrandi A, Scaroni C, Occhi G, Ceccato F, Regazzo D, De Menis E, Sartorato P, Arnaldi G, Tremantino L, Trimarchi F, Ferrau F.

*J Clin Endocrinol Metab* 2016; 101:1872-9. doi: 10.1210/jc.2015-4191. **IF: 5.455 Q1**

Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study.

Ferrau F, Romeo PD, **Puglisi S**, Ragonese M, Torre ML, Scaroni C, Occhi G, De Menis E, Arnaldi G, Trimarchi F, Cannavò S.

*Endocrine* 2016; 54:762-767. doi: 10.1007/s12020-016-0862-4. **IF: 3.131 Q2**

Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly.

Cannavò S, Ferrau F, Ragonese M, Romeo PD, Torre ML, **Puglisi S**, De Menis E, Arnaldi G, Salpietro C, Cotta OR, Albani A, Ruggeri RM, Trimarchi F.

*Clin Endocrinol* 2014; 81:249-53. doi: 10.1111/cen.12424. **IF: 3.457 Q2**

Cardiovascular events in acromegaly: distinct role of Agaston and Framingham score in the 5-year prediction.

Ragonese M, Alibrandi A, Di Bella G, Salamone I, **Puglisi S**, Cotta OR, Torre ML, Ferrau F, Ruggeri RM, Trimarchi F, Cannavò S.

*Endocrine* 2014; 47:206-12. doi: 10.1007/s12020-013-0115-8. **IF: 3.878 Q2**